Log In
Print this Print this

Relebactam/imipenem/cilastatin FDC

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionFixed-dose combination (FDC) of relebactam, a class A and C beta lactamase (LACTB) inhibitor, and imipenem/cilastatin
Molecular Target Beta lactamase (LACTB)
Mechanism of ActionBeta lactamase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationIntra-abdominal infection
Indication DetailsTreat complicated intra-abdominal infections (cIAIs)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today